LIXT

Lixte Biotechnology Holdings, Inc.

Regulated industry Physical products Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Fundamentals are temporarily unavailable for LIXT.

LIXT Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$1.35M	$898.10K	$726.23K	$254.92K
Selling, General & Admin	$4.96M	$4.19M	$2.85M	$4.85M
Operating Expenses	$6.31M	$5.09M	$3.57M	$5.11M
Operating Income	-$6.31M	-$5.09M	-$3.57M	-$5.11M
EBITDA	-$6.30M	-$5.07M	-$3.57M	-$6.00M
Pretax Income	-$6.31M	-$5.09M	-$3.59M	-$6.01M
Net Income	-$6.31M	-$5.09M	-$3.59M	-$6.01M
Diluted EPS	-3.99	-2.66	-1.59	-1.26
Diluted Shares	1.58M	1.92M	2.25M	4.84M

LIXT Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$5.35M	$4.20M	$1.04M	$5.11M
Current Assets	$5.56M	$4.31M	$1.15M	$5.18M
Total Assets	$5.56M	$4.31M	$1.15M	$12.73M
Current Liabilities	$395.76K	$313.86K	$318.28K	$1.33M
Total Debt	—	—	$0.00	$1.10M
Total Liabilities	$395.76K	$313.86K	$318.28K	$1.77M
Retained Earnings	-$43.39M	-$48.48M	-$52.07M	-$58.08M
Shareholders' Equity	$5.17M	$3.99M	$827.22K	$9.66M
Working Capital	$5.17M	$3.99M	$827.22K	$3.85M

LIXT Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$4.61M	-$4.29M	-$3.16M	-$3.07M
Free Cash Flow	-$4.61M	-$4.29M	-$3.16M	-$3.07M
Stock-Based Compensation	$1.55M	$773.20K	$418.42K	$1.56M
Investing Cash Flow	—	—	$0.00	-$3.17M
Financing Cash Flow	$5.14M	$3.14M	$0.00	$10.31M
Net Change in Cash	$529.65K	-$1.15M	-$3.16M	$4.07M

LIXT Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$91.46K	$60.65K	$50.70K	$52.12K	$333.38K
Selling, General & Admin	$615.48K	$714.16K	$1.75M	$1.77M	$1.65M
Operating Expenses	$706.94K	$774.81K	$1.80M	$1.82M	$1.99M
Operating Income	-$706.94K	-$774.81K	-$1.80M	-$1.82M	-$1.99M
EBITDA	-$706.42K	-$773.86K	-$1.98M	-$2.54M	-$1.98M
Pretax Income	-$709.55K	-$775.67K	-$1.98M	-$2.54M	-$1.99M
Net Income	-$709.55K	-$775.67K	-$1.98M	-$2.54M	-$1.92M
Diluted EPS	-0.29	-0.29	-0.33	—	-0.18
Diluted Shares	2.47M	2.72M	6.17M	—	10.89M

LIXT Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$1.38M	$887.21K	$2.89M	$5.11M	$3.25M
Current Assets	$1.51M	$989.75K	$5.43M	$5.18M	$3.41M
Total Assets	$1.51M	$1.19M	$5.43M	$12.73M	$10.87M
Current Liabilities	$355.10K	$537.12K	$521.42K	$1.33M	$1.22M
Total Debt	—	—	—	$664.49K	$595.42K
Total Liabilities	$355.10K	$537.12K	$521.42K	$1.77M	$1.69M
Retained Earnings	-$52.78M	-$53.55M	-$55.53M	-$58.08M	-$60.00M
Shareholders' Equity	$1.16M	$651.46K	$4.91M	$9.66M	$7.95M
Working Capital	$1.16M	$452.63K	$4.91M	$3.85M	$2.18M

LIXT Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$568.48K	-$487.49K	-$926.75K	-$1.09M	-$1.83M
Capital Expenditure	—	—	—	—	-$24.86K
Free Cash Flow	-$568.48K	-$487.49K	-$926.75K	-$1.09M	-$1.86M
Stock-Based Compensation	$99.74K	$268.00K	$821.32K	$370.87K	$82.18K
Investing Cash Flow	$0.00	—	—	-$535.10K	-$24.86K
Financing Cash Flow	$914.23K	-$10.00K	$5.56M	$3.84M	$0.00
Net Change in Cash	$345.75K	-$497.49K	$2.00M	$2.22M	-$1.86M

Market Snapshot

About

Lixte Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company developing cancer treatments targeting cancer signaling pathways. The company's research focuses on protein phosphatases and their role in cancer cell survival and proliferation. Lixte's lead drug candidates aim to inhibit specific pathways that tumors use to evade normal cellular controls. The company conducts clinical trials exploring its therapies for various cancer indications.